Decision Memorandum CAG#-00438N
entitled Transcatheter Mitral Valve Repair (TMVR) for Degenerative
Mitral Regurgitation was published August 7, 2014. In this
decision, CMS determined that it the evidence is sufficient to
cover TMVR under Coverage with Evidence Development for Medicare
beneficiaries under certain conditions only when the provider is
participating in and patients are enrolled in a qualifying clinical
studies meeting certain requirements. Consistent with section 1142
of the Social Security Act, the Agency for Healthcare Research and
Quality (AHRQ) supports clinical research studies that the CMS
determines meet specified standards and address the specified
research questions.
The changes to burden are due
to calculations based on averages of the actual number of TMVR
procedures performed since the original PRA package was created.
The original numbers were estimates that were not based on
experience as these were new processes at the time and they also
did not account for overhead and benefits. The number of
respondents decreased from 4,000 to 3,987. The burden hours
decreased from 5,600 to 5,456.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.